![]() ![]() Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. The heparin-protamine interaction: a review. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Das Protamin, eine neue organische Base aus den Samenfäden des Rheinlachses. ![]() Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. Molecular Therapy 2015, 3 (5), 791-792.Ĭushing DJ, Cooper WD, Cohen ML, McVoy JR, Sobel M, Harris RB. The Ups and Downs of Clinical Translation of New Technologies: Déjà Vu All Over Again. A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents. Use of PER977 to reverse the anticoagulant effect of edoxaban. PLoS ONE 2015, 10 (3), e0119486.Īnsell J, Bakhru SH, Laulicht SS, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin. Kalaska B, Kaminski K, Sokolowska E, Czaplicki D, Kujdowicz M, Stalińska K, Bereta J, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. Kalaska B, Sokolowska E, Kaminski K, Szczubialka K, Mogielnicki A, Nowakowska M, Buczko W. ![]() Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Shenoi, RA, Kalathottukaren, MT, Travers, RJ, Lai BFL, Creag AL, Lange D, Yu K, Weinhart M, Chew BH, Du C, Brooks DE, Carter CJ, Morrissey JH, Haynes CA, Kizhakkedathu JN. Heparin sensing and binding-taking supramolecular chemistry towards clinical applications. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Lowenstein E, Johnston WE, Lappas DG, D'Ambra MN, Schneider RC, Dagget WM, Akins CW, Philbin DM. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Nat Med 2013, 19, 446-451.Ĭook JJ, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart GJ, Mosser DM, Myers JA, Maione TE. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. Heart Disease and Stroke Statistics-2015 Update: a report from the American Heart Association. Mozzaffarian D, Benjamin EJ, Go AS, et al. Dostępny: (ostatnia aktualizacja Marzec 2016). Heparin Market – Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022”. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |